Traveller's diarrhoea vaccine - Emergent BioDefense Operations Lansing

Drug Profile

Traveller's diarrhoea vaccine - Emergent BioDefense Operations Lansing

Alternative Names: ACTIVAX

Latest Information Update: 28 Nov 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Developer Emergent BioDefense Operations Lansing; Johns Hopkins Bloomberg School of Public Health; Naval Medical Research Center; Nonindustrial source; Walter Reed Army Institute of Research
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Campylobacter infections; Escherichia coli infections; Shigella infections

Most Recent Events

  • 28 Nov 2007 Discontinued - Phase-I for Shigella infections in USA (PO)
  • 28 Nov 2007 Discontinued - Phase-II for Campylobacter infections in USA (PO)
  • 28 Nov 2007 Discontinued - Preclinical for Escherichia coli infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top